Patients with a higher expression level of PRMT5 had a worse prognosis for BLCA, head and neck squamous cell carcinoma (HNSC), LIHC, and SARC but a better prognosis for glioblastoma multiforme (GBM) and KIRC. Here, PRMT5 is linked to bladder transitional cell carcinoma.